Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Diabetes Institute; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China.
Chin Med J (Engl). 2023 Mar 5;136(5):522-527. doi: 10.1097/CM9.0000000000002582.
Glucose monitoring is an important part of medical care in diabetes mellitus, which not only helps assess glycemic control and treatment safety, but also assists with treatment adjustment. With the development of continuous glucose monitoring (CGM), the use of CGM has increased rapidly. With the wealth of glucose data produced by CGM, new metrics are greatly needed to optimally evaluate glucose status and guide the treatment. One of the parameters that CGM provides, time in range (TIR), has been recognized as a key metric by the international consensus. Before the adoption of TIR in clinical practice, several issues including the minimum length of CGM use, the setting of the target range, and individualized TIR goals are summarized. Additionally, we discussed the mounting evidence supporting the association between TIR and diabetes-related outcomes. As a novel glucose metric, it is of interest to compare TIR with other conventional glucose markers such as glycated hemoglobin A1c. It is anticipated that the use of TIR may provide further information on the quality of glucose control and lead to improved diabetes management.
血糖监测是糖尿病医疗护理的重要组成部分，不仅有助于评估血糖控制和治疗安全性，还有助于调整治疗方案。随着连续血糖监测（CGM）的发展，CGM 的使用迅速增加。随着 CGM 产生的大量血糖数据，非常需要新的指标来最佳评估血糖状态并指导治疗。CGM 提供的参数之一，即时间在目标范围内（TIR），已被国际共识认可为关键指标。在 TIR 在临床实践中应用之前，总结了包括 CGM 使用最短时间、目标范围设置和个体化 TIR 目标等几个问题。此外，还讨论了支持 TIR 与糖尿病相关结局之间关联的越来越多的证据。作为一种新型血糖指标，将 TIR 与糖化血红蛋白 A1c 等其他传统血糖标志物进行比较很有意义。预计 TIR 的使用可能会提供有关血糖控制质量的更多信息，并改善糖尿病管理。
